A5029318700- Hematopoietic Stem Cell Transplantation
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Acute Myeloid Leukemia Research
- Oral health in cancer treatment
- Neutropenia and Cancer Infections
- Oral and gingival health research
- Renal Transplantation Outcomes and Treatments
- Cytomegalovirus and herpesvirus research
- Parvovirus B19 Infection Studies
- Acute Lymphoblastic Leukemia research
- Polyomavirus and related diseases
- Virus-based gene therapy research
- Pancreatic function and diabetes
- Blood disorders and treatments
- Fungal Infections and Studies
- Antifungal resistance and susceptibility
- Cancer, Hypoxia, and Metabolism
- RNA Interference and Gene Delivery
- Multiple Sclerosis Research Studies
- Mesenchymal stem cell research
Karolinska University Hospital
2014-2023
Karolinska Institutet
2015-2022
During more recent years only few studies have analyzed the effect of total nucleated cell (TNC) and CD34+ dose in allogeneic hematopoietic stem transplantation (HSCT). A single-center analysis included 544 patients, 227 with a sibling donor 317 an unrelated donor. Most patients (n = 292) were treated myeloablative conditioning, whereas remaining 252) received reduced-intensity conditioning. Bone marrow (BM) 121) peripheral blood (PBSC) grafts 423) separately. Median TNC was 3.2 × 108/kg...
Improvement of graft-versus-host disease prophylaxis remains an important goal in allogeneic hematopoietic stem cell transplantation. Based on reports possibly preferential properties sirolimus, we compared the standard regimen cyclosporine and methotrexate (n=106) with a combination tacrolimus sirolimus (n=103) as after transplantation prospective, open, randomized trial. The hypothesis was that tacrolimus/sirolimus would lead to less acute reduced transplant-related mortality. There no...
Reduced-intensity conditioning/nonmyeloablative conditioning regimens are increasingly used in allogeneic hematopoietic cell transplantation (HCT). Reports have shown CD34(+) dose to be important for outcome using myeloablative conditioning. The role of peripheral blood progenitor cells (PBPC) has not been previously analyzed a large population undergoing reduced-intensity HCT. We studied 1054 patients, ages 45 75 years, with acute myeloid leukemia or myelodysplastic syndrome who underwent...
Chronic graft-versus-host disease (cGVHD) is a debilitating complication arising in around half of all patients treated with an allogeneic hematopoietic stem cell transplantation. Even though treatment severe cGVHD has improved during recent years, it remains one the main causes morbidity and mortality affected patients. Biomarkers blood that could aid diagnosis classification severity are needed for development novel strategies can alleviate symptoms reduce need painful sometimes...
Highlights•Type of graft-versus-host disease (GVHD) prophylaxis, aside from antithymocyte globulin, did not affect T cell receptor excision circle (TREC) or kappa-deleting recombination (KREC) levels after allogeneic hematopoietic stem transplantation (HSCT).•Younger recipient age and treatment with globulin had significant impacts on TREC levels.•Patients KREC above the median superior 5-year overall survival lower transplantation-related mortality.•Lower coincided onset acute GVHD...
An outbreak of human adenovirus (HAdV) A31 occurred from December 2011 to March 2012 at the Center for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital in Sweden. We analyzed outbreak, routes transmission, and report medical consequences.The records all patients admitted CAST during period were studied. Phylogenetic analysis patient HAdV strains was performed by sequencing hexon gene more variable E3 gene.We identified 9 cases A31. Hygiene measures implemented, but...
Invasive mold infections (IMIs) are major complications after allogeneic hematopoietic stem cell transplantation (HSCT) with high mortality. We retrospectively investigated incidence and risk factors for IMI 797 HSCTs in a center autopsy frequency, trying to identify patient groups that would potentially benefit from mold-active prophylaxis. The cumulative 1-year of was 2.1% patients aged 21 40, 7.1% 41 60, 16.4% > 60 years age (P < .01 40 versus P .001 60). Risk new multivariate analysis...
Abstract After ASCT , children are isolated in hospital to prevent neutropenic infections. Patients living within two‐h drive from the were given option of treatment at home after . Daily visits by an experienced nurse and phone calls a physician unit included protocol. We compared 29 adolescents treated with 58 matched controls. The spent median time 13 days (range 2–24 days) 6 (0–35) hospital. cumulative incidence acute GVHD grades II – IV was 21% home‐care 39% controls (p = 0.1). Chronic...
Outcome after allogeneic hematopoietic stem cell transplantation is influenced by patient comorbidity, disease type, and status before treatment. We performed a retrospective study involving 521 consecutive adult patients who underwent for hematological malignancy at our center from 2000 to 2012 compare the predictive value of transplantation-specific comorbidity index (HCT-CI) risk (DRI) overall survival transplantation-related mortality. Patients in highest HCT-CI group (HCT-CI score ≥3)...
Allogeneic hematopoietic stem cell transplantation (HSCT) is associated with several potentially lethal complications. Higher levels of CD3+ T-cells in the graft have been increased risk graft-versus-host disease (GVHD), but also beneficial graft-versus-leukemia effect and reduced infections. To tackle post-transplant complications, donor lymphocyte infusions used an GVHD. reduce this risk, we performed depletion αβ treated 12 patients post-HSCT suffering from infections and/or poor immune...
Background Lymphocyte neogenesis from primary lymphoid organs is essential for a successful reconstitution of immunity after allogeneic hematopoietic stem cell transplantation (HSCT). This single-center retrospective study aimed to evaluate T receptor excision circles (TREC) and kappa-deleting recombination (KREC) as surrogate markers B recovery, predictors transplantation-related outcomes in adult acute myeloid leukemia (AML) patients. Methods Ninety patients diagnosed with AML treated HSCT...
The aim of this study is to evaluate the incidence sinusoidal obstruction syndrome (SOS) liver and clinical outcome after hematopoietic stem cell transplantation (HSCT) based on several modifications in our protocols. We retrospectively investigated 372 patients undergoing myeloablative conditioning with oral busulfan (Bu) cyclophosphamide before allogeneic HSCT during 1990-2015. Patients' supportive care was changed order reduce regimen-related toxicities. Norethisterone use terminated...
To determine whether treatment with tacrolimus plus sirolimus (Tac/Sir) as a prophylaxis for graft-versus-host disease worsens severe oral mucositis and delays healing compared to cyclosporine methotrexate (CsA/Mtx) following haematopoietic stem cell transplantation.The study comprised 141 patients: 73 randomized receive Tac/Sir 68 CsA/Mtx. The assessment scale toxicity grading according WHO were used assess the severity, peak duration of from day -3 24 post-transplant.Eighty-seven patients...
Chronic graft-versus-host-disease (cGvHD) is a late complication (>90 days) after allogeneic hematopoietic stem cell transplantation (HSCT). Symptoms might occur in multiple organs and vary from mild to severe. In this study, the NIH criteria were used group patients. We performed an extensive immune-phenotypic analysis using cells plasma patients diagnosed with without cGvHD. The aim of study gain information on possible markers that could be by clinicians aid diagnosis
Chronic graft versus host disease (cGvHD) is a late complication (>90 days) post hematopoietic stem cell transplantation (HSCT). Multiple organs are affected and symptoms vary from mild to severe. We performed an extensive immune-phenotypic analysis on patients diagnosed with varying grades of cGvHD (according NIH criteria).
Sirolimus is an inhibitor of the mammalian target rapamycin (mTOR) and emerging as a promising component graft-versus-host disease (GVHD) prophylaxis regimens in context allogeneic hematopoietic stem cell transplantation (HSCT). Multiple studies have explored clinical benefits adding sirolimus to GVHD prophylaxis; however, detailed immunologic not yet been carried out this context. Mechanistically, mTOR at center metabolic regulation T cells natural killer (NK) critical for their...